A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Minesh P. Mehta(Columbia University), Kurt A. Jaeckle(Jacksonville College), David Schiff(University of Virginia), Walter J. Curran(Piedmont Cancer Institute), Robert Jeraj(University of Wisconsin–Madison), Deborah T. Blumenthal, Terri S. Armstrong(The University of Texas MD Anderson Cancer Center), Howard Colman(University of Utah), Erik P. Sulman(NYU Langone Health), Ivo W. Tremont‐Lukats(The University of Texas MD Anderson Cancer Center), Minhee Won(American College of Radiology), Kenneth Aldape(National Institutes of Health), Paul D. Brown(Mayo Clinic), Maria Werner‐Wasik(American College of Radiology), David Brachman(Barrow Neurological Institute), Arnab Chakravarti(The Ohio State University), Michael A. Vogelbaum(Moffitt Cancer Center), James J. Dignam(American College of Radiology), Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center), Stephanie L. Pugh(American College of Radiology), Volker W. Stieber(Southeast Clinical Oncology Research Consortium)
Cited by 2,786
Related Papers
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k